Actively Recruiting

Age: 18Years +
All Genders
NCT07358364

Remibrutinib in Real-world Clinical Practice

Led by Novartis Pharmaceuticals · Updated on 2026-04-16

3280

Participants Needed

1

Research Sites

299 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Prospective, multi-country, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.

CONDITIONS

Official Title

Remibrutinib in Real-world Clinical Practice

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a confirmed diagnosis of primary CSU by the treating physician.
  • Aged at least 18 years on the date of enrolment.
  • Written informed consent to participate and willingness to complete the 24-month follow-up.
  • Cohort 1: Inadequate control of CSU despite licensed dose of sgH1-AH with decision to escalate sgH1-AH treatment.
  • Cohort 2: Inadequate control of CSU despite licensed or escalated sgH1-AH(s) with decision to switch to remibrutinib.
  • Cohort 3: Any other treatment added to H1-AH during CSU history with decision to switch to remibrutinib; continuous steroids for at least 3 weeks during history included.
  • Patients must not have started the next treatment step before enrolment to capture baseline status.
Not Eligible

You will not qualify if you...

  • Currently enrolled in a clinical trial or receiving experimental treatment.
  • In safety follow-up phase of a previous study.
  • Previously received remibrutinib as an investigational product.
  • Unable or unwilling to provide continuous electronic patient-reported data.
  • Treated with remibrutinib outside of local label.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cleaver Dermatology

Kirksville, Missouri, United States, 63501

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here